| milligrams | 10mg, 30mg |
|---|

Semaglutide
- Research Grade
- 99% Purity
- Third-Party Verified
Semaglutide
R999,00
Semaglutide is a long-acting GLP-1 receptor agonist researched for chronic weight management, appetite regulation and glycaemic control. Its extended half-life supports convenient once-weekly administration in research settings.
Complimentary Purchase Kit
Every qualifying vial includes a complimentary purchase kit at no additional cost.
Research Overview
About Semaglutide
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1). By activating GLP-1 receptors it helps regulate appetite, glucose metabolism and energy balance, making it one of the most extensively studied peptides for obesity and metabolic research.
How It Works in Research
Semaglutide mimics the naturally occurring GLP-1 hormone released after eating. It binds to GLP-1 receptors in the brain to increase feelings of fullness, reduce appetite and decrease food cravings. It also slows gastric emptying, helping meals remain in the stomach longer and promoting prolonged satiety. In the pancreas, Semaglutide enhances glucose-dependent insulin secretion while reducing glucagon release, supporting improved glucose regulation. Structural modifications allow the peptide to bind to albumin and resist enzymatic breakdown, giving it an extended half-life of approximately seven days and making once-weekly dosing possible. These combined actions contribute to sustained weight loss and improved metabolic health when studied alongside appropriate lifestyle interventions.
Research Applications
Weight management Obesity research Appetite regulation Type 2 diabetes research Cardiometabolic health Insulin sensitivity
Key Research Characteristics
Long-acting GLP-1 receptor agonist
Approximately 7-day half-life Once-weekly administration Highly selective GLP-1 receptor activity Extensively studied in metabolic research
Potential Benefits in Research
Supports significant weight management
- Reduces appetite and food intake
- Improves glycaemic control
- Once-weekly administration
- Demonstrated cardiometabolic benefits in clinical research
Safety Profile
Commonly reported effects include nausea, vomiting, diarrhoea, constipation, abdominal discomfort and temporary injection-site irritation. Gradual dose escalation is commonly used to improve tolerability.
Research Applications
REFERENCE RECONSTITUTION INFORMATION
Always follow sterile preparation techniques when handling research peptides.
3ml Reconstitution Guide
Reference Parameters (Dosing Protocol (3ml Reconstitution))
| Phase | Dose | Units | Volume |
|---|---|---|---|
| Weeks 1–4 | 0.50mg | 5 Units | 0.05ml |
| Weeks 5–8 | 1.0mg | 10 Units | 0.10ml |
| Weeks 9–12 | 1.7mg | 17 Units | 0.17ml |
| Weeks 13–16 | 2.5mg | 25 Units | 0.25ml |
| Weeks 17+ | 3.0mg | 30 Units | 0.30ml |
View Certificate of Analysis
Only logged in customers who have purchased this product may leave a review.
Related products
-
Metabolic Research
Tirzepatide
R799,00 – R1699,00Price range: R799,00 through R1699,00 Select options This product has multiple variants. The options may be chosen on the product page -
Metabolic Research
Retatrutide
R899,00 – R1999,00Price range: R899,00 through R1999,00 Select options This product has multiple variants. The options may be chosen on the product page
Reviews
There are no reviews yet.
Only logged in customers who have purchased this product may leave a review.
FOR RESEARCH PURPOSES ONLY
This product is intended for research and laboratory use only. Always consult qualified researchers and follow appropriate safety protocols.





Reviews
There are no reviews yet.